Form 4: Organogenesis VP Sells Shares for Tax Obligation

Organogenesis Holdings Inc.'s Vice President of Strategy, Robert Cavorsi, disposed of 700 shares of Class A Common Stock to cover tax liabilities.

Summary

• Robert Cavorsi, Vice President, Strategy at Organogenesis Holdings Inc. (ORGO), reported a transaction involving Class A Common Stock.
• On March 1, 2026, Cavorsi disposed of 700 shares of Class A Common Stock.
• The disposal was executed at a price of $3.21 per share.
• This transaction was coded as 'F', indicating payment of tax liability by withholding securities.
• Following this transaction, Cavorsi beneficially owns 275,524 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The disposal of shares is for tax liability, a common and often pre-planned occurrence for executives, and does not indicate a change in company fundamentals or a lack of confidence.

Negatives

• The transaction resulted in a minor reduction of 700 shares in direct beneficial ownership by a key executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those marked as 'F' for tax withholding, are common occurrences in the public markets and typically do not reflect a change in the company's operational fundamentals or an executive's long-term confidence in the company. Such transactions are often pre-scheduled under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, which is generally not a significant concern given the nature of the transaction (tax withholding).

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction for tax purposes and does not provide new information that would warrant a change in investment recommendation. The disposal of 700 shares by the Vice President of Strategy is a common event for executives receiving equity compensation and does not signal a shift in company fundamentals or management's outlook. Investors should continue to evaluate Organogenesis Holdings Inc. based on its broader financial performance, strategic initiatives, and market position.

Keywords

Organogenesis, ORGO, Form 4, Insider Transaction, Stock Sale, Tax Liability, Beneficial Ownership, Executive Compensation